Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab

James A. Garrity, Austin W. Coleman, Eric Lawrence Matteson, Eric R. Eggenberger, David M. Waitzman

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor α in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis). Observational case series. Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti-inflammatory chemotherapeutic agents. All seven patients had a favorable response to treatment with infliximab. One patient with Behçet disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Behçet disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months). Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails.

Original languageEnglish (US)
Pages (from-to)925-930
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume138
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Orbital Myositis
Inflammation
Adrenal Cortex Hormones
Therapeutics
Infliximab
Psoriasis
Crohn Disease
Anti-Inflammatory Agents
Radiotherapy
Tumor Necrosis Factor-alpha
Monoclonal Antibodies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. / Garrity, James A.; Coleman, Austin W.; Matteson, Eric Lawrence; Eggenberger, Eric R.; Waitzman, David M.

In: American Journal of Ophthalmology, Vol. 138, No. 6, 12.2004, p. 925-930.

Research output: Contribution to journalArticle

Garrity, James A. ; Coleman, Austin W. ; Matteson, Eric Lawrence ; Eggenberger, Eric R. ; Waitzman, David M. / Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. In: American Journal of Ophthalmology. 2004 ; Vol. 138, No. 6. pp. 925-930.
@article{6f63be183a13489488f82db214cc7f89,
title = "Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab",
abstract = "To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor α in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis). Observational case series. Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti-inflammatory chemotherapeutic agents. All seven patients had a favorable response to treatment with infliximab. One patient with Beh{\cc}et disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Beh{\cc}et disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months). Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails.",
author = "Garrity, {James A.} and Coleman, {Austin W.} and Matteson, {Eric Lawrence} and Eggenberger, {Eric R.} and Waitzman, {David M.}",
year = "2004",
month = "12",
doi = "10.1016/j.ajo.2004.06.077",
language = "English (US)",
volume = "138",
pages = "925--930",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab

AU - Garrity, James A.

AU - Coleman, Austin W.

AU - Matteson, Eric Lawrence

AU - Eggenberger, Eric R.

AU - Waitzman, David M.

PY - 2004/12

Y1 - 2004/12

N2 - To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor α in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis). Observational case series. Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti-inflammatory chemotherapeutic agents. All seven patients had a favorable response to treatment with infliximab. One patient with Behçet disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Behçet disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months). Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails.

AB - To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor α in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis). Observational case series. Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti-inflammatory chemotherapeutic agents. All seven patients had a favorable response to treatment with infliximab. One patient with Behçet disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Behçet disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months). Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails.

UR - http://www.scopus.com/inward/record.url?scp=11144286438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144286438&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2004.06.077

DO - 10.1016/j.ajo.2004.06.077

M3 - Article

VL - 138

SP - 925

EP - 930

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -